GSK enters its Q1 2026 results on April 29 carrying a stock down 6% on the week and a short book that has quietly unwound heading into the print.
The most telling positioning signal is how dramatically short sellers have pulled back. Short interest has fallen from a local peak of 0.75% of the free float in early April to just 0.52% now — a decline of roughly one-third in under four weeks. Borrowing costs remain negligible at 0.60%, and utilization is well below 1%, far short of its 52-week high of 1.86%. The lending market is completely untapped, which means the recent price weakness has not come from a new wave of short selling — rather, it reflects broader sector pressure.
That context matters because GSK's peers are also under strain. AZN fell nearly 4% on the day and close to 8% on the week. NOVN dropped more than 2% and 4% respectively. MRK shed 6% over the past week. GSK's 6% weekly decline is therefore largely in line with a sector-wide retreat, rather than a stock-specific breakdown — which reframes the setup as macro-driven rather than fundamental deterioration.
The investment debate centres on where GSK's growth profile can go from here. Headline fundamentals are undemanding: the stock trades at a P/E of around 10.9x and EV/EBITDA near 8.1x, with the dividend score sitting in the 98th percentile — placing it among the highest-yielding names in the universe. EPS momentum over 30 days ranks in the 61st percentile, suggesting forward estimates are holding up better than the price action implies. The analyst consensus mean price target of £20.49 sits just above the current price of £20.16, leaving little implied upside even before accounting for target-price inertia. The EPS surprise factor ranks only in the 33rd percentile, which means the company does not have a strong recent track record of beating estimates — a consideration as Q1 comparisons become more demanding.
On the ownership side, the most notable recent move is from the GSK Employee Trust, which trimmed its stake by 12.4 million shares in its last reported period. BlackRock and FMR both added meaningfully — 41.3 million and 47.2 million shares respectively — suggesting institutional anchor holders remain constructive even as the trust reduced exposure. Insider activity at the director level has been modestly net positive in recent weeks, with two independent director purchases recorded since mid-February, though both were small in scale.
The last earnings release in February produced a 12% single-day move and a 10.5% gain over five days — the strongest near-term reaction visible in recent history. The April 29 print will therefore test whether that momentum was a one-off re-rating or the start of a durable recovery, against a backdrop of sector-wide selling and a consensus that has not yet rewarded the stock with meaningful upside.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
